Abstract: The development and metasis of malignant tumor depend on neovascularization.CD13 is a significant marker of cells commit to myeloid lineage to classify leukemia, meanwhile it expresses on the neovascular endothelial cells specifically but expresses barely in vascular endothelial cells.Coupling CD13 monoclonal antibody or CD13 ligand to CD13 in fluorescence, radionuclide or magnetic nanoparticles to achieve molecular imaging to probe angiogenesis and provide imaging evidence of the development of angiogenesis associated disease.Asn-Gly-Arg peptide motif compound with different anticancer drugs targeted deliver to neovascular endothelial cells and release the anticancer drugs to treat the tumor.The research of CD13 to understand, diagnose and treat the angiogenesis associated diseases has gotten breakthrough and have a promising future.